Know Cancer

or
forgot password

A Patient Cohort With Locally Advanced or Metastatic Non-small Cell Lung Cancer Treated With Tarceva (Erlotinib) Monotherapy and Not Progressing After at Least 9 Months


N/A
18 Years
N/A
Open (Enrolling)
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Patient Cohort With Locally Advanced or Metastatic Non-small Cell Lung Cancer Treated With Tarceva (Erlotinib) Monotherapy and Not Progressing After at Least 9 Months


Inclusion Criteria:



- Adult patients, >/=18 years of age

- Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC, stage
III/IV)

- Treatment with Tarceva monotherapy and not progressing after at least 9 months at the
date of study start

Exclusion Criteria:

- Not agreeing to be followed-up (for a maximum of 24 months)

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Progression-free survival

Outcome Time Frame:

24 months

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

France: Commission Nationale de l'Informatique et des Libert├ęs (CNIL)

Study ID:

ML22973

NCT ID:

NCT01488331

Start Date:

June 2010

Completion Date:

July 2013

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location